Alcon Inc (ALC)

La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada

L’utilisation du système combiné pour la chirurgie vitréorétinienne et la chirurgie de la cataracte...

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years...

NovaAlgoma Cement Carriers Establishes New JV With DP World

NovaAlgoma Cement Carriers Limited (“NovaAlgoma"), a joint venture between Algoma Central Corporation (“Algoma” - TSX: ALC) and Nova Marine...

Alcon Canada reçoit une reconnaissance mondiale comme l’un des meilleurs employeurs

Certification de meilleur employeur au Canada décernée par le Top Employers Institute La stratégie en matière de ressources humaines, le...

Alcon annonce l’arrivée de Clareon PanOptix Pro au Canada, une lentille intraoculaire réduisant la dispersion de la lumière comme aucune autre LIO trifocale

Clareon PanOptix Pro réduit la dispersion de la lumière de moitié par rapport à PanOptix1-3,*,** PanOptix Pro utilise 94 % de la lumière, une...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter...

Alcon Announces Results of 2025 Annual General Meeting

Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on...

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

First-to-market innovations enhance efficiency, including HYPERVIT 30K, the world’s fastest vitrectomy probe...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alcon Publishes Agenda for 2025 Annual General Meeting

Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member...

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of...

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset...